Petra Acquisition, Inc. (NASDAQ:PAIC), in a press release today regarding it’s Phase 2b trials for REVTx-99, also announced that its shareholders approved its combination with biotech firm Revelation Biosciences in a meeting held last week.
Unfortunately, nothing has been filed yet and Petra did not disclose much information regarding the deal, including redemption figures. However, the combined company is expected to begin trading today on the Nasdaq under “REVB” and “REVBW”.
The SPAC recently added forward purchase agreements and a convertible note that added up to $12 million to its combination with Revelation. Of this amount, $4.5 million is to be used to backstop potential redemptions with financing from AXA Prime Impact Master Fund, LifeSci Venture Partners as well as other Petra and Revelation institutional investors. Meteora Capital and affiliates have also agreed to purchase 750,000 shares from redeeming shareholders and have agreed not to redeem themselves.
Petra initially announced its $128 million combination with Revelation on August 30. San Diego-based Revelation is developing two drug candidates aimed at treating respiratory diseases as well as a diagnostic device for diagnosing viral infections.
On December 1, it initiated Phase 2b trials for REVTx-99 to test its efficacy in treating the flu while this drug began Phase 1b trials for treating allergic rhinitis and chronic nasal congestion the month before.
ADVISORS
- Roth Capital Partners is acting as financial advisor to Revelation
- LifeSci Capital is acting as financial and capital markets advisor to Petra
- Loeb & Loeb LLP is acting as legal counsel to Petra
- Fox Rothschild LLP and J.P. Galda & Co are acting as legal counsel to Revelation
Terms Tracker for the Week Ending June 20, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Two more SPACs priced IPOs this week, one each from Cohen and Cantor. That brings June’s IPO count to five and the 2025 year-to-date tally...
CSLM Digital Asset (NASDAQ:KOYNU) has filed for a $200 million IPO to hunt for a crypto transaction with a team that includes veterans from a variety of other SPAC efforts. The new SPAC sports 1/2 warrants in units and will have 24 months to initially close a business combination. It becomes the 16th SPAC that...
At the SPAC of Dawn The past year has seen a string of serial sponsor teams return to market, with some already listing multiple vehicles in a full return to the hunt. One prolific SPAC leader that has been conspicuously absent from this return so far has been Chamath Palihapitiya, who has been a part...
BM Acquisition Corp. (NASDAQ:BMOKU) has filed for a $60 million IPO to bring another first-time, Asia-based team to the market. The new SPAC is serving up 1/2 warrants in each of its units and the team will have 18 months under its initial search window to close a deal. It may extend this, but only...
At the SPAC of Dawn The Fed’s rate decision day has finally come and futures are slightly green in anticipation. De-SPACs have largely opted not to hedge their bets on the event with several making large-scale equity capital raises directly on its eve. Four companies alone raised over $1 billion in secondary offerings this week,...